Cargando…
Nedaplatin: a cisplatin derivative in cancer chemotherapy
Nedaplatin, a cisplatin analog, has been developed to decrease the toxicities induced by cisplatin, such as nephrotoxicity and gastrointestinal toxicity. The dose of nedaplatin is determined by body surface area, not by the area under the curve (AUC). The recommended therapeutic dose is 80–100 mg/m(...
Autores principales: | Shimada, Muneaki, Itamochi, Hiroaki, Kigawa, Junzo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658440/ https://www.ncbi.nlm.nih.gov/pubmed/23696716 http://dx.doi.org/10.2147/CMAR.S35785 |
Ejemplares similares
-
Cisplatin‐resistant HeLa Cells Are Resistant to Apoptosis via p53‐dependent and ‐independent Pathways
por: Minagawa, Yukihisa, et al.
Publicado: (1999) -
Synergistic Enhancement of Cisplatin Cytotoxicity by SN‐38, an Active Metabolite of CPT‐11, for Cisplatin‐resistant HeLa Cells
por: Minagawa, Yukihisa, et al.
Publicado: (1994) -
Enhanced Topoisomerase I Activity and Increased Topoisomerase IIα Content in Cisplatin‐resistant Cancer Cell Lines
por: Minagawa, Yukihisa, et al.
Publicado: (1997) -
Comparative Nephrotoxicity of Cisplatin and Nedaplatin: Mechanisms and
Histopathological Characteristics
por: Uehara, Takeki, et al.
Publicado: (2011) -
Neoadjuvant Chemotherapy with Fluorouracil plus Nedaplatin or Cisplatin for Locally Advanced Nasopharyngeal Carcinoma: a Retrospective Study
por: Liu, Tongxin, et al.
Publicado: (2018)